TR1X emerged from stealth with a $75 million Series A financing in January 2024 to bring universal allogeneic regulatory T (Treg) and CAR-Treg cell therapies to the clinic to treat and potentially cure autoimmune and inflammatory diseases. Tr1X's proprietary technology enables the conversion of CD4+ T cells isolated from healthy donors into Treg-like cells that have a similar function and profile to naturally occurring Tr1 cells.

The company is headquartered in San Diego and has developed a robust intellectual property portfolio, and is backed by leading investors, including The Column Group, NEVA SGR and Alexandria Ventures.